Tag: KDC-MN-049

Choline bitartrate is the tartaric acid salt of choline, a quaternary ammonium compound recognized as an essential nutrient by the United States Institute of Medicine in 1998. The salt form contains approximately 41 percent choline by mass and is the most widely manufactured and least expensive choline supplement form in global commerce. Choline itself is a precursor to acetylcholine (synthesized by choline acetyltransferase from choline and acetyl-coenzyme A), to the membrane phospholipid phosphatidylcholine (synthesized by the cytidine diphosphate-choline or Kennedy pathway), and to the methyl donor betaine (synthesized by choline dehydrogenase and betaine aldehyde dehydrogenase in a two-step mitochondrial oxidation), which donates methyl groups to homocysteine in the betaine-homocysteine methyltransferase reaction. These three metabolic fates underwrite a broad physiological role that spans neurotransmission, membrane structural integrity, hepatic very-low-density lipoprotein assembly, one-carbon metabolism, and epigenetic regulation of gene expression through histone and DNA methylation. Pharmacokinetic studies in healthy volunteers demonstrate rapid oral absorption with peak plasma choline concentrations achieved within one to two hours after ingestion of a single dose. However, choline bitartrate delivers choline as the free water-soluble cation, which is subject to substantial first-pass hepatic extraction and gut microbial conversion to trimethylamine before systemic distribution. Gut microbial trimethylamine production and subsequent hepatic flavin-containing monooxygenase 3 oxidation to trimethylamine N-oxide represent both a metabolic loss pathway and a potential cardiovascular risk signal, as elevated circulating trimethylamine N-oxide concentrations have been associated with increased atherosclerotic cardiovascular disease incidence in prospective cohort studies. Compared to phospholipid-conjugated choline sources (alpha-glycerophosphocholine, cytidine diphosphate-choline, phosphatidylcholine from egg yolk or krill oil), choline bitartrate produces higher peak trimethylamine N-oxide levels and lower incremental phosphatidylcholine enrichment in plasma, reflecting differential metabolic routing. The clinical evidence base for choline bitartrate as a standalone supplement is mixed. Controlled feeding studies at the National Institutes of Health and at the University of North Carolina have established that dietary choline deprivation produces hepatic steatosis, elevated serum aminotransferase, and muscle damage in both men and women within weeks, confirming essentiality in humans. Epidemiological studies link higher dietary choline intake to reduced risk of nonalcoholic fatty liver disease and to reduced neural tube defect incidence in offspring of pregnant women. However, placebo-controlled trials of acute choline bitartrate supplementation in healthy young adults have failed to demonstrate significant enhancement of declarative memory or working memory, although improvements in visuomotor performance and pupil constriction have been reported. Chronic supplementation data in rodent models show cognitive and locomotor improvements accompanied by reduced oxidative stress. The evidence is more favorable for cognitive benefit in elderly populations and in individuals with diagnosed choline deficiency, consistent with the compound functioning as a conditional nootropic whose benefit depends on baseline choline status. The Institute of Medicine established Adequate Intake values of 550 mg per day for adult men and 425 mg per day for adult women, with 450 mg per day during pregnancy and 550 mg per day during lactation. The Tolerable Upper Intake Level for adults is 3500 mg of choline per day; adverse effects above the upper limit include hypotension, fishy body odor (from trimethylamine excretion), sweating, gastrointestinal distress, and hepatotoxicity. Population surveys indicate that the majority of adults in North America and Europe consume choline below the Adequate Intake, and fewer than 10 percent of pregnant women meet gestational requirements. This monograph reviews the chemistry, synthesis, and salt-form characteristics of choline bitartrate; the three-arm molecular pharmacology (acetylcholine synthesis, phospholipid biosynthesis, methyl donation); comprehensive pharmacokinetics including the trimethylamine N-oxide pathway; the clinical evidence base across cognitive, hepatic, gestational, and cardiovascular endpoints; sourcing and quality verification; reconstitution and handling; stack interactions with other cholinergic, nootropic, and hepatoprotective agents; adverse events and safety signals including the trimethylamine N-oxide cardiovascular association; and a comparative assessment of five alternative choline-delivery compounds (alpha-glycerophosphocholine, cytidine diphosphate-choline, phosphatidylcholine, choline chloride, and centrophenoxine) against choline bitartrate on five competency standards (bioavailability and brain penetration, effect size on cognitive endpoints, breadth of clinical evidence, side-effect profile, and cost-effectiveness).